J. M. Hamby

发表

Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.

C. Humblet, J. Rubin, H. D. Showalter, 1998, Journal of medicinal chemistry.

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain

S. Hubbard, J. Schlessinger, M. Mohammadi, 1998, The EMBO journal.

Overview: Recent Advances in Angiotensin II Receptor Antagonists

J. M. Hamby, D. T. Dudley, J. Hamby, 1993 .

Topographically designed peptidomimetic inhibitors of human renin: Incorporation of novel, tethered P1 → P3 side chain functionalization

C. Humblet, E. Lunney, J. M. Hamby, 1994 .

Design and synthesis of renin inhibitors: incorporation of transition-state isostere side chains that span from the S1 to the S3 binding pockets and examination of P3-modified renin inhibitors.

C. Humblet, E. Lunney, A. Doherty, 1995, Journal of medicinal chemistry.

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the P1(→ P3)-P1' sites

J. M. Hamby, M. Plummer, G. Hingorani, 1993 .

Synthesis of Amino 1,3-Diols. Ring Opening of N-Acyl Activated Lactams with Carbon Nucleophiles

J. M. Hamby, M. Reily, M. Taylor, 1993 .

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

A. Doherty, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

a-Amino Ketones from Amino Acids as Precursors for the Knorr Pyrrole Synthesis

J. M. Hamby, J. C. Hodges, 1993 .

Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

A. Doherty, D. W. Fry, J. M. Hamby, 1997 .

Synthesis of Amino 1,3-Diols, e.g. (V) - (VIII). Ring Opening of N- Acyl Activated Lactams, e.g. (I), with Carbon Nucleophiles, e.g. (II), (XI).

J. M. Hamby, M. Reily, M. Taylor, 1993 .

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.

A. Doherty, H. D. Showalter, J. M. Hamby, 2001, Journal of medicinal chemistry.

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.

W. Denny, H. D. Showalter, J. M. Hamby, 2000, Journal of medicinal chemistry.

Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonists.

J. M. Hamby, R. Panek, J. C. Hodges, 1995, Journal of medicinal chemistry.

A comparison of nucleophilic reactions of 3-benzenesulfonyloxyalloxazine and its 1-methyl analog†

J. M. Hamby, L. Bauer, J. Hamby, 1987 .

Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.

J. M. Hamby, C. Shih, R. Moran, 1989, Journal of medicinal chemistry.

A Comparison of Nucleophilic Reactions of 3-Benzenesulfonyloxyalloxazine and Its 1-Methyl Analog.

J. M. Hamby, L. Bauer, 1988 .

Inhibitors of Glycinamide Ribonucleotide Formyltransferase as Potential Cytotoxic Agents. Synthesis of 5-Deaza-5,6,7,8-tetrahydrohomofolic Acid, 5-Deaza-5,6,7,8-tetrahydroisohomofolic Acid, and 10-Formyl-5-deaza-5,6,7,8-tetrahydroisohomofolic Acid

J. M. Hamby, C. Yoon, E. Taylor, 1994 .

Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors.

H. D. Showalter, J. M. Hamby, J. Hamby, 1999, Pharmacology & therapeutics.

In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.

A. Doherty, J. M. Hamby, R. Panek, 1997, The Journal of pharmacology and experimental therapeutics.

Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.

J. M. Hamby, A. Kraker, R. Panek, 1997, The Journal of pharmacology and experimental therapeutics.